Therapeutic Lipidology Table of Contents
Lipoprotein Metabolism and Vascular Biology
Brian G. Choi, M.D., M.B.A.
Juan J. Badimon, Ph.D.
Pedro R. Moreno, M.D.
Valentin Fuster, M.D., Ph.D.
Lipoprotein Metabolism Regulation
Lipids in Vascular Biology and Atherothrombosis
Genetic Disorders of Lipoprotein Metabolism
Marina Cuchel, M.D., Ph.D.
Atif Qasim, M.D.
Daniel J. Rader, M.D.
Lipid Disorders Involving Elevated Triglycerides
Inherited Syndromes of Elevated LDL-Cholesterol
Inherited Syndromes of Low LDL-Cholesterol
Inherited Syndromes of Low HDL-C
Inherited Syndromes of Elevated HDL-C Levels
International Guidelines for Dyslipidemia Management
Cathleen E. Maki, R.N., M.S.N., N.P.
The Canadian Guidelines
The European Guidelines
Joint British Societies Guidelines
Pathophysiology and Management of Dyslipidemias Associated with
Obesity, Type 2 Diabetes and Other Insulin Resistant States
Kevin C. Maki, Ph.D.
Obesity and Type 2 Diabetes Mellitus
Cardiometabolic Risk Syndrome
Lipid Abnormalities Associated with Insulin Resistance
Functions of Insulin
Excessive Production of Very-low Density Lipoproteins (VLDL): The
Primary Lipid Abnormality in the Insulin Resistant State
Reasons for Elevated Free Fatty Acid Levels in Insulin Resistant States
Formation of Small, Dense LDL Particles
Mechanisms Linking Insulin Resistance to Low HDL Cholesterol
Activities of Lipoprotein and Hepatic Lipases and Their Relationships
to Atherogenic Dyslipidemia
Lifestyle Management for Atherogenic Dyslipidemia
Drug Therapies for Atherogenic Dyslipidemia
Intensification of Efforts to Lower LDL-C as a Means of Achieving the
Targeting Triglyceride-rich Lipoprotein Reduction as a Means of
Management of Diabetic Dyslipidemia
C-Reactive Protein and Other Inflammatory Markers in Cardiovascular
Natalie Khuseyinova, M.D.
Wolfgang Koenig, M.D., Ph.D.
Markers of Hemostasis, that are also Acute Phase Reactants
Plasminogen Activator Inhibitor-1
Von Willebrand Factor
White Blood Cell Count
Oxidised (Ox) LDL
Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk
Margo A. Denke, M.D.
A Diet-Enthusiast's Summary of The Evolving Role of Diet
Pre-Statin Cholesterol Lowering (1960-1987)
Early Statin Years: LDL Lowering (1987-1994)
Landmark Statin Trials, LDL Lowering and Eruption of the Metabolic
Lipid Therapy Beyond LDL and CHD Prevention Dietary Therapies Beyond
Pharmacological Therapy for Cardiovascular Disease: Current and
Michael H. Davidson, M.D., F.A.C.C., F.A.C.P.
Bile Acid Sequestrants
Omega-3 Fatty Acids
Effects of Thiazolidinediones on Serum Lipoproteins
Anjli Maroo, M.D., R.V.T.
W. H. Wilson Tang, M.D., F.A.C.C.
Mechanisms of TZD Actions on Serum Lipoproteins
Clinical Evidence of Lipid Lowering Effects of TZDs
Meta-Analyses of Pioglitazone and Rosiglitazone Trials
Prospective Comparative Clinical Studies
Concomitant TZD and Statin Therapy
Peter P. Toth, M.D., Ph.D.
Antiatherogenic Effects of HDL
Epidemiologic Studies Evaluating the Relationship between HDL and Risk
for Cardiovascular Disease
The Definition and Prevalence of Low HDL
Effects of Lifestyle Modification on HDL
Pharmacologic Therapy for Lowshow more